Case 21-1103: Federal Circuit Affirms Unpatentability of US9840743B2
In a Rule 36 judgment issued without opinion, the U.S. Court of Appeals for the Federal Circuit affirmed the unpatentability of US9840743B2 — a patent covering systems and methods to detect rare mutations and copy number variation. The appeal ran for 836 days before reaching its final disposition on 9 February 2023.
Federal Circuit Affirms Unpatentability of Rare Mutation Detection Patent
Case 21-1103 is an appeal before the U.S. Court of Appeals for the Federal Circuit concerning the patentability of US9840743B2 (application number US15/467570), a patent directed to systems and methods for detecting rare mutations and copy number variation. The appeal was filed on 26 October 2020 and closed on 9 February 2023, spanning 836 days. The underlying verdict cause is recorded as an invalidity/cancellation action on patentability grounds.
The recorded basis of termination is 'Unpatentable.' The docket order states: 'THIS CAUSE having been heard and considered, it is ORDERED and ADJUDGED: AFFIRMED. See Fed. Cir. R. 36.' The Federal Circuit thus affirmed the tribunal below without issuing a written opinion, invoking its summary affirmance procedure under Rule 36. No party names, agent names, or law firm names are disclosed in the available record.
An 836-day appellate timeline is broadly consistent with Federal Circuit appeals from PTAB proceedings. The use of Rule 36 suggests the court found no substantial question warranting a written opinion, which typically signals that the lower tribunal's reasoning was regarded as sound on the record presented. No information about the identity of the appellant or appellee, the specific invalidity grounds, or any licensing implications is available in the public record.
See Complete Case & Patent Analysis →Filing to Unpatentable in 836 days
836 days from filing to Federal Circuit disposition — consistent with typical PTAB appeal timelines
US9840743B2 — Rare Mutation and Copy Number Variation Detection
R&D teams and product counsel working on rare mutation detection platforms, copy number variation analysis tools, or next-generation sequencing diagnostic systems should be aware that US9840743B2 has been adjudged unpatentable by the Federal Circuit. While this specific patent no longer represents an active enforcement risk, related continuation applications or family members covering similar subject matter may remain in prosecution or in force. An FTO analysis confined to this single patent number may give an incomplete picture of the risk landscape.
Official order — verbatim text
The court's order — 'AFFIRMED. See Fed. Cir. R. 36' — is the Federal Circuit's summary affirmance procedure, indicating the panel found no reversible error in the lower tribunal's unpatentability determination. Under the applicable appellate standard of review, legal conclusions on patentability are reviewed de novo and factual findings for substantial evidence. The absence of a written opinion means no new precedent was set, but the unpatentability of US9840743B2 is now final at this court level.
Federal Circuit affirms: what the ruling means for both parties
Affirmance under Rule 36: no reversible error found
A Federal Circuit Rule 36 affirmance is a summary judgment that the lower tribunal committed no reversible error. The court issues no written opinion. The prior ruling — finding US9840743B2 unpatentable — stands in full. Rule 36 is applied when the Federal Circuit determines the appeal raises no novel legal question requiring elaboration.
Summary affirmance, no written opinionPatent invalidated: enforceability extinguished
For the patent holder, the Rule 36 affirmance confirms that US9840743B2 — covering systems and methods to detect rare mutations and copy number variation — is unpatentable. The patent cannot be enforced. Further challenge options at the Federal Circuit level are exhausted; only a petition for certiorari to the Supreme Court would remain as a potential avenue, and such petitions face a very high threshold.
Patent unenforceableChallenger prevails: patent claim eliminated
The party that successfully challenged patentability before the lower tribunal has had that outcome affirmed. The unpatentability finding is now final at the Federal Circuit level. Competitors and implementers of rare mutation and copy number variation detection technology no longer face the threat of infringement claims under US9840743B2, at least based on this patent.
Invalidity affirmedCleared IP landscape for mutation detection technology
The confirmed unpatentability of US9840743B2 removes a potential IP barrier in the rare mutation detection and copy number variation analysis space. Companies developing next-generation sequencing, liquid biopsy, or oncology diagnostic platforms that may have been concerned about this patent's claims can note that the patent is no longer valid. Related patents in the same family or covering adjacent claims should still be independently assessed.
Freedom-to-operate signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Plaintiff | Individual | Party identity not disclosed in the available record — appellant in patentability appealSearch in Eureka ↗ |
| Defendant | Defendant | Individual | Party identity not disclosed in the available record — appellee in patentability appealSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the rare mutation and CNV detection space
Forward-looking patent and R&D intelligence derived from the invalidation of US9840743B2 and the broader rare mutation and copy number variation detection technology domain.
Prosecution activity around US15/467570 and its patent family
The invalidation of US9840743B2 may prompt the original applicant to pursue continuation or continuation-in-part applications with refined claim sets designed to distinguish the prior art that caused cancellation. Monitoring the prosecution history and any new filings stemming from application US15/467570 is a high-priority action for competitors in rare mutation detection.
Family filing watchFiling trends in rare mutation detection and CNV analysis
Rare mutation detection and copy number variation analysis represent a high-growth filing area driven by NGS cost reductions and expanding clinical applications in oncology. Patent filing activity in this space has intensified among diagnostics companies, sequencing platform vendors, and academic medical centres. Understanding the density and direction of recent filings helps R&D teams identify white space and freedom-to-operate corridors.
Active filing landscapeCompetitor patent positions in CNV and rare variant diagnostics
With US9840743B2 removed from the competitive landscape, R&D teams should assess which other players hold active patents in overlapping technical areas — particularly in error-correction algorithms, allele frequency calling, and sequencing depth normalisation methods used in CNV detection. Understanding competitor portfolio depth informs both design-around strategy and partnership risk.
Competitor landscapeAdjacent innovation opportunities near invalidated CNV detection claims
The prior art that rendered US9840743B2 unpatentable defines the boundary of what was known — and may also illuminate adjacent technical approaches that remain less densely patented. Methods combining CNV detection with epigenomic signals, multi-modal rare variant calling, or AI-driven somatic mutation filtering may represent white-space filing opportunities for innovators in the liquid biopsy and molecular diagnostics field.
Innovation white spaceSimilar Federal Circuit patentability appeals in genomic diagnostics
Explore Federal Circuit appeals involving PTAB unpatentability findings in the genomic diagnostics, rare mutation detection, and copy number variation analysis space.
What this case signals for the genomic diagnostics IP landscape
A Rule 36 affirmance of unpatentability in the rare mutation detection space sends a clear signal to patent holders and challengers alike.
Rule 36 affirmances carry full legal weight despite their brevity
A Federal Circuit Rule 36 judgment is not a lesser outcome — it is a binding affirmance. For companies monitoring US9840743B2 as a freedom-to-operate risk, this ruling confirms the patent is unpatentable. Product teams and IP counsel in the NGS and liquid biopsy space can remove this patent from active risk registers, though related applications warrant review.
Unpatentability findings do not automatically clear related family members
US9840743B2 (application US15/467570) may sit within a broader patent family. An unpatentability finding on this specific patent does not resolve the status of continuation, divisional, or related applications covering similar subject matter. R&D teams in rare mutation and copy number variation detection should conduct a full family search before assuming a cleared path.
Plaintiff v Defendant — key questions answered
The Federal Circuit affirmed the unpatentability of US9840743B2 in Case 21-1103, issuing a summary judgment under Rule 36 on 9 February 2023. The judgment states: 'AFFIRMED. See Fed. Cir. R. 36.' The recorded basis of termination is 'Unpatentable.' No written opinion was issued.
A Rule 36 affirmance means the Federal Circuit found no reversible error in the lower tribunal's determination that US9840743B2 is unpatentable. The court issues no written opinion. The unpatentability finding is binding and final at the Federal Circuit level. The patent cannot be enforced. The only remaining avenue would be a petition for certiorari to the U.S. Supreme Court.
No. The unpatentability finding applies specifically to US9840743B2 (application US15/467570). Related patents in the same family, continuation applications, or third-party patents covering overlapping subject matter in rare mutation and copy number variation detection may remain active. A full patent family and landscape search is required before drawing broader FTO conclusions.
US9840743B2 covers systems and methods to detect rare mutations and copy number variation — core capabilities in next-generation sequencing, liquid biopsy platforms, and molecular oncology diagnostics. The patent's scope is directly relevant to companies developing clinical-grade rare variant detection tools, CNV callers, and somatic mutation analysis pipelines.
The available public record for Case 21-1103 does not disclose the names of the appellant, appellee, their legal representatives, or associated law firms. No party identification is available from the data provided. The case involves an invalidity/cancellation action concerning the patentability of US9840743B2.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.